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nical specifications; de-identified data were aggregated by CAQH to determine adher-
ence to beta blocker therapy overall, by region, and by type of health plan product.
Adherence was defined as claims for at least 75% “days supply” of beta-blocker during a
measurement interval.
Results: The study population included 15,070 patients from 44 states in 9 CAQH mem-
ber health plans (45% HMO/POS, 27% Medicare + Choice, 24% PPO, 4% Indemnity).
Adherence for 3, 6, 9, and 12 months was 55%, 52%, 49%, and 46%, respectively,
across all insurance products and regions. There was a pattern of declining adherence to
beta-blockers over time from discharge after MI in all insurance products and all geo-
graphic regions. Cumulative national population adherence for HMO/POS products for 3,
6, 9, and 12 months were 57%, 54%, 52%, and 49% respectively. Adherence for Medi-
care + Choice patients for the same intervals was lower: 49%, 46%, 42%, and 39%. In
comparison, 2001 HEDIS data estimated a mean of 92% for prescription of beta-blockers
within 7 days of discharge after MI.
Conclusion: Despite having prescription and commercial insurance coverage, less than
50% of this large population were still taking beta-blockers one year after MI. In order to
capture the survival benefit potentially afforded by beta-blockers, quality improvement ini-
tiatives need to focus on longer term outpatient adherence.
11:30 a.m.
838-5 Enrollment Disparities on the Basis of Age and Chronic 
Disease Burden in Cardiovascular Clinical Trials: Are 
Patients’ Decisions the Reason?
Anand Parekh, Neil R. Powe, Joel B. Braunstein, Johns Hopkins Medical Institutions, 
Baltimore, MD
Background: Randomized controlled trials have been criticized for enrolling select
groups of patients, while excluding those most representative of the population under
study. In cardiovascular disease, this concern implies inadequate representation of
patients who are older and have multiple comorbidities. We determined willingness to
participate (WTP) in a cardiovascular clinical trial among a community-based sample of
patients with these characteristics.
Methods: We approached 1440 randomly selected individuals from 13 Maryland-based
outpatient cardiology and internal medicine clinics to complete a brief self-administered
survey, which contained a 1-page description of an efficacy trial of a new drug for preven-
tion of myocardial infarction. We measured WTP on a 5-point Likert response scale (+
response = Very likely/ likely). Patients provided demographic and socioeconomic infor-
mation, along with a report of their comorbidity burden, measured by presence of condi-
tions included in the Deyo-Charlson case-mix severity index.
Results: Of 1132 patients eligible, 789 (70%) patients responded. Patients were mean
aged 54 ±16 (range 18-89) years, 51% female, and 35% black, with a median of 2 comor-
bidities (range 0-11). Older-aged patients (> 75 years)(n=79) were less WTP than
younger patients (19% vs. 36%, p<0.01). Patients with more extensive comorbidity, how-
ever, were no less WTP than those with less extensive comorbidity (WTP = 29% if no
comorbidity, 34% if 1 comorbidity, 35% if 2-4 comorbidites, 39% if > 5 comorbidites,
p=0.43). In multivariable logistic regression, after adjusting for race, gender, income, and
education, older age was associated with a 65% lower likelihood of WTP (OR, 95% CI =
0.35, 0.19-0.64; p=0.001), while each categorical increase in comorbidity was associated
with a 19% higher likelihood of WTP (1.19, 1.00-1.42; p<0.05).
Conclusion: While older age is independently associated with lower WTP in cardiovas-
cular clinical trials, more extensive comorbidity is not. These findings warrant consider-
ation in the design of future trials, which seek to adequately enroll cardiac patients who
are most representative of those encountered in routine clinical practice.
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838-6 The Impact of Prior Myocardial Infarction, Metabolic 
Syndrome, and High White Blood Cell Count on 
Coronary Heart Disease Mortality: The Multiple Risk 
Factor Intervention Trial (MRFIT) 18-Year Follow-Up 
Experience
Jerome D. Cohen, Ronald J. Prineas, Xin Zhi, Lynn E. Eberly, Lewis H. Kuller, James D. 
Neaton, The MRFIT Research Group, University of Minnesota, Minneapolis, MN, St. 
Louis University, St. Louis, MO
Background: Predictors of coronary heart disease (CHD) mortality include history of
myocardial infarction (MI), metabolic syndrome (MS) and inflammatory markers. MRFIT
data are used to examine their impact on CHD mortality over 18 years.
Methods: At the end of 6 years of follow-up there were a total of 11,357 men with mea-
sures of MI, MS and inflammatory markers. MI during the study ( n=208) was docu-
mented by records and /or ECG. Metabolic syndrome (n=4,761) was defined by ATP III
guidelines with at least 3 of the following present: obesity (BMI>30 kg/m² as a surrogate
for waist circumference), hypertension (blood pressure >130/85 mm Hg or on drugs), low
HDL cholesterol (<40 mg/dl), high fasting triglycerides (>150 mg/dl) and high fasting glu-
cose (>110 mg/dl). WBC above the median (6,900/µL) was used as a marker for inflam-
mation (n=5,679). Post-trial mortality was ascertained using the National Death Index.
Results: There were 1,257 CHD deaths after 18 years. The table shows the hazard
ratios for CHD mortality after adjustment for age, race, treatment group, smoking status
at entry and year 6 and average LDL cholesterol during follow-up. Similar results were
seen with total and CVD mortality.
Conclusions: The impact of each of these risk factors on CHD mortality is highly signifi-
cant and additive. These simple assessments can identify high risk patients who can be
targeted for appropriate medical management.
Hazard Ratios (HR) for CHD Mortality by Presence/Absence of MS,
WBC >6,900/µL and/or Prior MI 
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1153-67 Patient Attitudes in Clinical Trials: The PACT Survey
Milan Gupta, Blanche Aaron, Janice Burtcher, Nicoletta Bonafede, David Borts, 
Brampton Research Associates, Brampton, ON, Canada, William Osler Health Centre, 
Brampton, ON, Canada
Background: Little is known about patient attitudes towards informed consent and par-
ticipation in cardiovascular clinical trials (CT). We surveyed 430 consecutive participants
in 8 large in-patient (IP) and out-patient (OP) trials between 1998-2002 through a mailed
survey twice over 3 months.
Results: Of 430 participants, 37 (8.6%) died prior to study completion, and 242 (61.6%)
responded to the survey (69% male). Similar proportions had participated in IP and OP
CT (46.7% vs. 53.3%). The majority were 50-69 years old (59.8%), with 35.7% >age 69,
with no difference in age distribution between genders. The majority had a high school
(38.7%) or university degree (28.5%) and were unemployed or retired (66.9%). Most
patients had read the study consent form (87.6%), and 3.5% found the consent form too
difficult to understand. Women were more likely to feel pressured to join their CT than
men (16.2% vs. 5.5%, p=0.024). Side effects attributed to study drug were common
among women (27.5% vs. 11.9%, p=0.005), but early drug termination was similar
between genders (7.3% vs. 5.6%). The majority f (74.4%) were willing to participate in
future CT. Other differences noted:
Conclusions: CT participants are satisfied with informed consent and are willing to par-
ticipate in future trials.Women are more likely to feel pressured into joining, and to experi-
ence study-related side effects. The consent process is sub-optimal for participants of in-
patient clinical trials, and warrants further investigation.
1153-68 Do Patients With Heart Failure Have a Medically 
Accurate Mental Image of Their Illness (also known as 
Illness Representation)?
Nancy M. Albert, The Cleveland Clinic Foundation, Cleveland, OH
Background: HF self-care behaviors modulate symptoms, morbidity and prognosis but
adherence is inconsistent. Mental image of an illness or illness representation (REP)
influences coping and behavior. Attributes of REP that influence behavior in other chronic
conditions are identity (label, silent processes, symptoms), time-line (duration), conse-
quences (prognosis) and control (self-care actions). Medically inaccurate HF-REP may
negatively impact self-care adherence. There are no published reports of the medical
accuracy of patients HF-REP. Methods: 104 chronic systolic HF patients completed a 33-
item Likert scale of HF-REP statements. Patient sum score (range 33-132) determined
the level of HF-REP medical accuracy and item mean score (range 1-4) specified items
of low and high medical accuracy. Demographic and medical history data were used to
determine predictors of medically accurate HF-REP. Instrument Cronbach's alpha was
.8535; validity testing completed. Results: Mean age was 61.8 ± 13.13; 66% of patients
had HF for > 2 years. Mean sum score was 98.8, reflecting medically accurate HF-REP.
Thirty patients (28%) scored in the mixed medically accurate-inaccurate range (72-93)
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6,900/ 
µL
MI No. 
Men
% 
Total
No.CHD 
Deaths
HR CHD 
Death
95% CI
- - - 3,395 (29.9) 265 1.0 
(reference)
- - + 47 (0.4) 13 3.7 (2.1-6.5)
- + - 3,084 (27.2) 302 1.2 (1.0-1.5)
+ - - 2,182 (19.2) 220 1.4 (1.2-1.7)
- + + 70 (0.6) 19 3.9 (2.4-6.4)
+ - + 32 (0.3) 12 5.6 (3.0-10.2)
+ + - 2,488 (21.9) 393 2.2 (1.9-2.6)
+ + + 59 (0.5) 33 10.7 (7.4-15.6)
% IP Participants % OP Participants p
Understood consent form 68.0 89.0 0.0002
Received copy of consent 49.1 70.5 0.0023
Felt pressure to join study 15.4 3.1 0.003
GP aware of participation 47.6 79.5 <0.0001
Would participate again 65.5 82.2 0.003
